Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors
CONCLUSION: The non-inferiority of NHT in relation to NCT will provide further evidence that replacing NCT with NHT is safe and effective in eligible patients, which is particularly relevant for populations with limited access to health services and for institutions with few available resources.PMID:36262803 | PMC:PMC9574413 | DOI:10.1016/j.conctc.2022.101013
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Maria Carolina Gouveia Candice Amorim de Ara újo Lima Santos Ariani Impieri Souza Source Type: research
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | HER2 | Hormonal Therapy | Hormones | Men | Menopause | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Women